Valuation: Exelixis, Inc.

Market Cap 13.3B 69.09B 11.39B 10.65B 9.76B 18.34B 1,273B 18.7B 126B 49.13B 638B 49.95B 48.87B 2,116B P/E 2026 *
16.6x
P/E 2027 * 14.1x
Enterprise Value 12.56B 65.23B 10.75B 10.05B 9.21B 17.31B 1,202B 17.66B 119B 46.38B 602B 47.16B 46.13B 1,997B EV / Sales 2026 *
4.92x
EV / Sales 2027 * 4.07x
Free-Float
98.15%
Yield 2026 *
-
Yield 2027 * -
1 day-0.22%
1 week+4.59%
Current month-1.82%
1 month+2.66%
3 months+12.85%
6 months+19.92%
Current year+14.89%
1 week 137.4
Extreme 137.4
138.3
1 month 131.95
Extreme 131.95
140.56
Current year 104.72
Extreme 104.72
140.56
1 year 98.24
Extreme 98.24
140.56
3 years 50.71
Extreme 50.71
140.56
5 years 40
Extreme 40
140.56
10 years 40
Extreme 40
140.56
Manager TitleAgeSince
Chief Executive Officer 65 2010-07-21
Director of Finance/CFO 58 2015-07-14
Chief Operating Officer 63 2016-01-31
Director TitleAgeSince
Director/Board Member 70 2004-01-31
Director/Board Member 82 2004-07-31
Chairman 77 1997-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-0.22%+4.59% - - 13.48B
+2.38%+5.57%+86.02%+115.89% 72.21B
+0.87%+16.32%+58.35%+97.28% 63.98B
-4.27%-5.44%-1.67%+475.61% 28.53B
+3.63%+8.62%+66.69%+23.95% 25.07B
-1.97%+19.57%-0.46%+0.48% 28.42B
-0.51%+5.11%+41.27%-12.79% 20.04B
-1.79%-4.51%+241.26%+414.48% 18.19B
+1.81%+0.85%+16.89%+546.06% 15.96B
-1.29%+6.57%+43.10%+154.45% 13.48B
Average -0.14%+5.63%+61.27%+201.71% 31.76B
Weighted average by Cap. +0.36%+7.48%+61.64%+163.91%

Financials

2026 *2027 *
Net sales 2.55B 13.25B 2.18B 2.04B 1.87B 3.52B 244B 3.59B 24.18B 9.42B 122B 9.58B 9.37B 406B 2.87B 14.91B 2.46B 2.3B 2.11B 3.96B 275B 4.04B 27.2B 10.6B 138B 10.78B 10.54B 456B
Net income 821M 4.26B 703M 657M 602M 1.13B 78.53B 1.15B 7.78B 3.03B 39.33B 3.08B 3.01B 131B 974M 5.06B 834M 780M 715M 1.34B 93.24B 1.37B 9.23B 3.6B 46.7B 3.66B 3.58B 155B
Net Debt -744M -3.87B -637M -596M -546M -1.03B -71.24B -1.05B -7.06B -2.75B -35.68B -2.8B -2.73B -118B -1.62B -8.43B -1.39B -1.3B -1.19B -2.24B -155B -2.28B -15.38B -5.99B -77.77B -6.09B -5.96B -258B
Logo Exelixis, Inc.
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Employees
1,077
Date Price Change Volume
26-08-19 R$137.40 -0.65% 4
26-08-18 R$138.30 +4.81% 1
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
54.39USD
Average target price
53.00USD
Spread / Average Target
-2.56%

Quarterly revenue - Rate of surprise